Literature DB >> 9583600

Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis.

E F Bowen1, V C Emery, P Wilson, M A Johnson, C C Davey, C A Sabin, D Farmer, P D Griffiths.   

Abstract

OBJECTIVES: To determine whether recurrence of polymerase chain reaction (PCR) viraemia during maintenance ganciclovir for cytomegalovirus (CMV) retinitis correlates with (i) CMV disease at a new anatomical site, (ii) progression of the presenting retinitis, or (iii) acquisition of genetic changes in gene UL97 associated with resistance to ganciclovir.
DESIGN: A previously described cohort of 45 patients presenting with first episode retinitis was followed clinically using ophthalmoscopy and serial tests for PCR viraemia for a median of 7 months. CMV viral load and genetic markers of ganciclovir resistance were measured in PCR-positive samples.
METHODS: PCR amplification of the glycoprotein B region of CMV and quantitative competitive PCR assays were employed. Genetic changes in UL97 were identified by sequencing/point mutation assay.
RESULTS: PCR viraemia correlated significantly with new episodes of CMV disease (P=0.011) and a trend was seen for the association with progression of retinitis (P=0.07). Amongst the 14 patients PCR-positive during maintenance ganciclovir, 10 (71%) had genetic markers of resistance. None of these patients became PCR-negative in blood after reinduction ganciclovir therapy compared with three out of four without markers of resistance (P=0.022).
CONCLUSIONS: CMV PCR viraemia correlated strongly with the development of new episodes of CMV disease. Most patients with progression of retinitis remained PCR-negative in blood, consistent with therapeutic failure due to poor intraocular penetration of ganciclovir. However, the minority who were PCR-positive in blood may have reinfected their eye, and frequently had markers of ganciclovir resistance. The implications of these findings for the management of patients with CMV disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9583600     DOI: 10.1097/00002030-199806000-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  13 in total

Review 1.  Is cytomegalovirus viraemia a useful tool in managing CMV disease?

Authors:  J R Deayton
Journal:  Sex Transm Infect       Date:  2000-10       Impact factor: 3.519

2.  Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I.

Authors:  Anne-Marie Fillet; Laetitia Auray; Sophie Alain; Karine Gourlain; Berthe Marie Imbert; Fatiha Najioullah; Gael Champier; Stéphanie Gouarin; Jocelyne Carquin; Nadhira Houhou; Isabelle Garrigue; Alexandra Ducancelle; Danielle Thouvenot; Marie-Christine Mazeron
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 3.  Antiviral drug resistance.

Authors:  D Pillay; M Zambon
Journal:  BMJ       Date:  1998-09-05

4.  Comparison of cytomegalovirus loads in plasma and leukocytes of patients with cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.

Authors:  D A Jabs; M Forman; C Enger; J B Jackson
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

5.  Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.

Authors:  N S Lurain; A Weinberg; C S Crumpacker; S Chou
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 6.  Cytomegalovirus reactivation in patients infected with HIV: the use of polymerase chain reaction in prediction and management.

Authors:  E F Bowen
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

7.  The dynamics of human cytomegalovirus replication in vivo.

Authors:  V C Emery; A V Cope; E F Bowen; D Gor; P D Griffiths
Journal:  J Exp Med       Date:  1999-07-19       Impact factor: 14.307

8.  Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy.

Authors:  V C Emery; P D Griffiths
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 9.  Investigation of CMV disease in immunocompromised patients.

Authors:  V C Emery
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

Review 10.  Pathogenesis of human cytomegalovirus in the immunocompromised host.

Authors:  Paul Griffiths; Matthew Reeves
Journal:  Nat Rev Microbiol       Date:  2021-06-24       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.